Importance of the host genetic background on immune responses to Helicobacter pylori infection and therapeutic vaccine efficacy.
In order to investigate the role of host factors in Helicobacter pylori infection and immunity, two different strains of inbred mice, C57BL/6 and BALB/c, were infected with a standard H. pylori strain, SS1. A month later, infected mice were immunized orally with whole-cell lysates of H. pylori SS1 and cholera toxin on days 1, 3, 6, 30, and 54. Ten days after the last immunization, mice were sacrificed and the stomach was collected to assess H. pylori colonization density by quantitative culture. H. pylori SS1 colonization was significantly greater in C57BL/6 than in BALB/c (P<0.02 and P<0.003 at 2 and 13 weeks post-inoculation, respectively). Colonization in C57BL/6 persisted at equivalent levels for 13 weeks but the colonization density in BALB/c decreased significantly during this period. In contrast to the pattern of bacterial colonization, antibody responses following H. pylori SS1 infection were greater in BALB/c than in C57BL/6, suggesting that host factors may modulate the immune responses to H. pylori infection. Following therapeutic immunization, H. pylori colonization in BALB/c mice was also significantly reduced (P<0.03), while no significant differences in bacterial density were observed in C57BL/6. These observations collectively demonstrate the great importance of host factors in H. pylori infection and the development of effective immune responses.
Kim
J S
JS
H. pylori team, Mogam Biotechnology Research Institute, 341 Pojung-ri, Koosung-myon, Yongin-city, 449-910, Kyonggi-do, South Korea. jangskim@greencross.com
Chang
J H
JH
Chung
S I
SI
Yum
J S
JS
D000276:Adjuvants, Immunologic; D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D000942:Antigens, Bacterial / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004195:Disease Models, Animal; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000235:genetics / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000235:genetics / Q000382:microbiology; D016480:Helicobacter pylori / Q000276:immunology / Q000302:isolation & purification; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D016233:Immunotherapy, Active; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D013045:Species Specificity; D013047:Specific Pathogen-Free Organisms; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D007071:Immunoglobulin A, Secretory; D007074:Immunoglobulin G